Literature DB >> 3129164

Alteration in osteoblast activity and nutritional vitamin-D deficiency in non-hypercalcemic malignancy.

P S Jowell1, S Epstein, F Ismail, B Hollis, I R Schwartz.   

Abstract

The biochemical parameters of bone mineral metabolism in patients with nonhypercalcemic malignancy have not been extensively investigated. Therefore, a group of 29 such patients with different types of malignancy was studied. Ten patients received corticosteroids. In the entire group, serum ionized calcium (Ca2+), bone gla protein (BGP), 25-hydroxyvitamin D (25OHD), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were all lower than in age-matched controls, and carboxy-terminal parathyroid hormone (CPTH) was higher. Although both corticosteroid- and noncorticosteroid-treated patients had decreased BGP values, the corticosteroid-treated patients had lower BGP levels than those not on steroids (4.24 +/- 0.70 SE vs. 11.50 +/- 2.20 ng/ml; P less than 0.005). Patients on corticosteroids had lower 1,25(OH)2D values than controls (18.81 +/- 2.71 vs. 27.83 +/- 1.17 pg/ml; P less than 0.01), whereas those not on corticosteroids had normal 1,25(OH)2D values. These results suggest that patients with nonhypercalcemic malignancy have nutritional vitamin-D deficiency and secondary hyperparathyroidism with perhaps corticosteroid-induced suppression of serum 1,25(OH)2D and BGP. The decreased levels of serum BGP in the nonsteroid-treated patients suggest, in addition, a defect in osteoblast function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129164     DOI: 10.1007/bf02555834

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  28 in total

1.  Low plasma-25-hydroxyvitamin D without osteomalacia.

Authors:  M Davie; D E Lawson; R T Jung
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

2.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

3.  Effect of 1,25-dihydroxyvitamin D3 on osteopenia induced by prednisolone in adult rats.

Authors:  J U Lindgren; C R Merchant; H F DeLuca
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

4.  Radioimmunoassay for the N-terminal, C-terminal and middle region of human parathyroid hormone in bone diseases.

Authors:  G Francini; R Nami; S Gonnelli; A Groppa; M Montagnani; C Gennari
Journal:  Quad Sclavo Diagn       Date:  1982-12

5.  Parathyroid function in different stages of vitamin D deficiency rickets.

Authors:  K Kruse; H Bartels; U Kracht
Journal:  Eur J Pediatr       Date:  1984-01       Impact factor: 3.183

6.  Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3.

Authors:  L M Sandler; C G Winearls; L J Fraher; T L Clemens; R Smith; J L O'Riordan
Journal:  Q J Med       Date:  1984

7.  Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.

Authors:  D M Slovik; C M Gundberg; R M Neer; J B Lian
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

8.  The effect of Prednisolone upon the metabolism and action of 25-hydroxy-and 1,25-dihydroxyvitamin D3.

Authors:  M Carré; O Ayigbedé; L Miravet; H Rasmussen
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

9.  Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.

Authors:  C M Gundberg; D E Cole; J B Lian; T M Reade; P M Gallop
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

10.  Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis.

Authors:  J E Zerwekh; K Sakhaee; C Y Pak
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.